npc 12626 has been researched along with deferoxamine in 1 studies
| Studies (npc 12626) | Trials (npc 12626) | Recent Studies (post-2010) (npc 12626) | Studies (deferoxamine) | Trials (deferoxamine) | Recent Studies (post-2010) (deferoxamine) |
|---|---|---|---|---|---|
| 55 | 0 | 0 | 6,703 | 240 | 1,266 |
| Protein | Taxonomy | npc 12626 (IC50) | deferoxamine (IC50) |
|---|---|---|---|
| Lysine-specific demethylase 4A | Homo sapiens (human) | 3.275 | |
| Deoxyhypusine hydroxylase | Homo sapiens (human) | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, S; Helfaer, MA; Hurn, PD; Traystman, RJ | 1 |
1 other study(ies) available for npc 12626 and deferoxamine
| Article | Year |
|---|---|
Parallel antioxidant and antiexcitotoxic therapy improves outcome after incomplete global cerebral ischemia in dogs.
Topics: Amino Acids; Animals; Antioxidants; Blood Glucose; Carbon Dioxide; Cerebrovascular Circulation; Deferoxamine; Dogs; Drug Therapy, Combination; Energy Metabolism; Evoked Potentials, Somatosensory; Excitatory Amino Acid Antagonists; Intracranial Pressure; Ischemic Attack, Transient; Magnetic Resonance Spectroscopy; Male; Oxygen; Partial Pressure; Receptors, N-Methyl-D-Aspartate; Reperfusion | 1997 |